Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Chia K, et al. Among authors: tilley wd. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333. Endocr Relat Cancer. 2019. PMID: 30557851
Role of the androgen receptor in human breast cancer.
Birrell SN, Hall RE, Tilley WD. Birrell SN, et al. Among authors: tilley wd. J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103. doi: 10.1023/a:1018730519839. J Mammary Gland Biol Neoplasia. 1998. PMID: 10819508 Review.
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD. Buchanan G, et al. Among authors: tilley wd. Cancer Res. 2005 Sep 15;65(18):8487-96. doi: 10.1158/0008-5472.CAN-04-3077. Cancer Res. 2005. PMID: 16166329 Free article.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Marrocco DL, et al. Among authors: tilley wd. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11. Mol Cancer Ther. 2007. PMID: 17218635
246 results